Also debuts TMR'09 campaign
IRVINE, Calif., Oct. 14 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a global leader of innovative therapies for ischemic cardiac disease and the market leader of surgical products for transmyocardial revascularization (TMR), sponsored an educational symposium yesterday in conjunction with the 20th Annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C.
The symposium, titled "New Horizons in Cardiac Regenerative Medicine: Advancements in Revascularization & Stem Cell Therapy," was attended by over 120 cardiology healthcare practitioners. The Program Chair was Warren Sherman, MD, Director of Cardiac Cell Based Endovascular Therapies, Center for Interventional Vascular Therapy, New York-Presbyterian Hospital/Columbia University Medical Center. Presenters included: Emerson Perin, MD, PhD, Director, New Interventional Cardiovascular Technology, Texas Heart Institute; Marvin Slepian, MD, Director of Interventional Cardiology, University of Arizona, Sarver Heart Center; and Keith Allen, Cardiothoracic Surgeon, Mid America Heart and Thoracic surgeons, Kansas City, MO.
"The program was designed to provide an update to clinicians on the recent developments with advanced cardiovascular revascularization and regenerative therapies, with a focus on patients suffering from ischemic cardiac disease," Dr. Sherman stated. "TCT attendees are eager to learn about rapidly evolving therapies, as well as the latest information on optimizing outcomes with available tools and techniques, including TMR as a sole therapy and adjunctive to bypass surgery."
Dr. Allen emphasized to the cardiologists in attendance, "Surgeons are innovating with Cardiogenesis to provide TMR with minimally invasive approaches, including surgical robotic delivery." He also discussed the early clinical experience with the PHOENIX combination delivery system being collected from centers outside the U.S.
As a leading clinical investigator of autologous stem cell trials, Dr. Perin provided a state of the art overview of cardiovascular stem cell clinical trials. He concluded, "The tissue-stimulated zone generated by TMR, along with the precise delivery of stem cells, may prove to be more potent in combination than either therapy alone."
TMR'09 campaign assists in ID of patients that TMR can help
"We understand the trust and respect with which a heart patient views recommendations and treatment options from his or her cardiologist," said Richard Lanigan, President of Cardiogenesis. "A focus of our TMR'09 campaign is to provide cardiologists with the latest information on the clinical utility of TMR and to assist them in identifying and educating patients who can benefit. We will build on this event in driving the awareness of the benefits of TMR with cardiologists and patients, as well as the advantages provided with our minimally invasive PEARL delivery systems."
About Cardiogenesis Corporation
Cardiogenesis is a global leader in providing new and innovative therapeutic solutions for ischemic cardiac disease. The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform an FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease.
With the exception of historical information, the statements set forth above include forward-looking statements. Any forward-looking statements in this news release related to the possible effectiveness of the company's PHOENIX delivery system or other technologies and the effect of such system or technology on the company's sales, profitability, the adoption of its technology and products and FDA clearances are based on current expectations and beliefs and are subject to numerous risks and uncertainties, many of which are outside the company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR or PMC procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the company to ship product on a timely basis; the company's ability to manage its growth; adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; restrictions contained in our convertible debt obligations requiring the issuance of shares rather than repayment in cash; and the company's ability to protect its intellectual property. Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the company's Annual Report on Form 10-KSB for the year ended December 31, 2007 and the company's other recent SEC filings. The company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
|SOURCE Cardiogenesis Corporation|
Copyright©2008 PR Newswire.
All rights reserved